Veraxa Biotech

Closed (deSPAC)

Healthcare · Oncology biopharma — bispecific T-cell engagers and antibody-drug conjugates

What it is: A private company in healthcare preparing to list via a SPAC merger. Full profile in progress.
What it’s doing now: Merging with Voyager (VACH) — closed (despac).
What you should know: Data is still being assembled for this company — what is shown below is everything we have verified so far.

Profile in progress — we only publish what we can verify in filings, and for this company that work isn’t finished. Identity and deal facts above are current; business detail, financials and peers will appear as the filings are parsed.

What the company says about itself

Web research — not audited

The website describes VERAXA Biotech as a company focused on superior cancer therapeutics using transformative innovations, specifically next-generation Antibody-Drug Conjugates (ADCs) and novel antibody formats. They highlight a strong foundation in ADCs with a lead program in clinical studies for Acute Myeloid Leukemia (AML), aiming to provide safer treatments with fewer side effects.

Markets:: Cancer Therapeutics | Biotechnology
Products:: Next-generation ADCs | Novel antibody formats | Lead program in clinical studies in AML

Source: https://www.veraxa.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Veraxa Biotech is merging with Voyager (VACH), a $253M SPAC currently marked Closed (deSPAC).

Headline equity value

—

Structure per SEC accession(s) 0001829126-25-002874. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Veraxa Biotech going public?

Veraxa Biotech has an approved merger with the SPAC Voyager (VACH). Deal status: Closed (deSPAC).

Does Veraxa Biotech have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other healthcare deals

Nanyang Biologics — with RFAI ($1.5B) · pre-revenue
DRC Medicine — with RIBB ($350M)
Talawar Therapeutics — with JATT ($120M) · pre-revenue
First Choice Healthcare — with WSTN ($650M)
Minovia Therapeutics — with LPAA ($180M)

Same sponsor’s other SPACs

TACH — Titan · Deal announced